1342P Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study.

Subjects

Subjects :

*EPIDERMAL growth factor receptors
*NON-small-cell lung carcinoma
*THERAPEUTICS
*PATIENTS

Details

Language :

English

ISSN :

09237534

Volume :

31

Database :

Academic Search Index

Journal :

Annals of Oncology

Publication Type :

Academic Journal

Accession number :

152696184

Full Text :

https://doi.org/10.1016/j.annonc.2020.08.1656